--- title: "DSGN.US (DSGN.US) — Related News" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/DSGN.US/news.md" symbol: "DSGN.US" name: "DSGN.US" parent: "https://longbridge.com/en/quote/DSGN.US.md" datetime: "2026-05-19T17:49:48.900Z" locales: - [en](https://longbridge.com/en/quote/DSGN.US/news.md) - [zh-CN](https://longbridge.com/zh-CN/quote/DSGN.US/news.md) - [zh-HK](https://longbridge.com/zh-HK/quote/DSGN.US/news.md) --- # DSGN.US (DSGN.US) — Related News ### [Pre-market hot trades in US stocks: Clinical data causes fluctuations, Design Therapeutics pre-market down 5.79%, where is market sentiment heading?](https://longbridge.com/en/news/286916197.md) *2026-05-19T12:52:20.000Z* > Design Therapeutics pre-market down 5.79%; Amesite pre-market up 191.31%; InMed Pharmaceuticals pre-market up 168.84%; R ### [U.S. stock night trading volatility: Design Therapeutics fell 3.46% in after-hours trading, as positive news failed to counteract market sentiment fluctuations](https://longbridge.com/en/news/286851146.md) *2026-05-19T04:01:25.000Z* > Design Therapeutics fell 3.46% in the after-hours market; BeiGene rose 1.22% in the after-hours market, with a transacti ### [Top 10 US Stock Losers (5.18)](https://longbridge.com/en/news/286823638.md) *2026-05-18T22:00:41.000Z* > Design Therapeutics(DSGN) fell 25.54%, with a trading turnover 90.0 Million USD, and a year-to-date rose 14.1%. Rackspac ### [](https://longbridge.com/en/news/286818680.md) *2026-05-18T20:59:39.000Z* > The Nasdaq Biotechnology Index closed down 1.85%. Among its components, Gossamer Bio fell 43.29%, Design Therapeutics dr ### [Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside](https://longbridge.com/en/news/286810211.md) *2026-05-18T19:20:03.000Z* > Design Therapeutics, Inc. stock's 12-month price target has been raised to $20, indicating a 39% upside from the previou ### [This Biotech Leader Ran Up As Much As 18% — And Then Lost It All](https://longbridge.com/en/news/286798319.md) *2026-05-18T16:02:43.000Z* > Shares of Design Therapeutics experienced a significant surge on Monday following positive results in the treatment of F